TD Cowen Maintains Buy on Krystal Biotech, Raises Price Target to $403
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
TD Cowen analyst Ritu Baral maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $306 to $403.
TD Cowen analyst Ritu Baral maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $306 to $403.